A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
Completed · Phase 1, Phase 2 · NCT02659020
Conditions: Soft Tissue Sarcoma
At a glance
- Research payments reported, 2025
- $8,142
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 310
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Olaratumab (drug), Gemcitabine (drug), Docetaxel (drug), Placebo (drug)
- Dates
- Started 2016-03-01; completion 2021-04-27
- Results posted
- Yes
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
From ClinicalTrials.gov, last updated 2022-05-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $8,142 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Trustees of Columbia Univ in The City of Ny $8,142
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.